Oral BPC-157 capsules Standard oral capsules: Contains BPC-157 powder Take on empty stomach Lower bioavailability (only small amount absorbed) Works directly on stomach/gut lining as it passes through Dosing: 500-1,000mcg daily (higher than injectable due to poor absorption) Split into 1-2 doses Take 30 minutes before meals Best for: Stomach ulcers IBS and digestive issues Leaky gut Esophageal issues Oral stable BPC-157 (Arginate or Acetate) Better oral absorption: BPC-157 Arginate or BPC-157 Acetate Modified to resist stomach acid breakdown Higher bioavailability than standard oral More expensive Dosing: 250-500mcg daily (similar to injectable) Can work systemically when absorbed Still best for gut issues How to take: Empty stomach preferred 30 minutes before food With water Don't take with acidic beverages Sublingual administration (under tongue) Some users try sublingual: Hold under tongue for 60-90 seconds May improve absorption vs swallowing No definitive evidence it's better Worth trying if you have capsules How to do it: Open capsule Pour powder under tongue Hold as long as possible Swallow saliva after 60-90 seconds BPC-157 dosing protocols by condition How much to take depends on what you're treating
Water retention, scale weight, and what to expect Research measuring total body water has found that short-term creatine loading can increase body water by about 2 liters and bump scale weight by around 1 kilogram, so you should treat early scale increases as hydration shifts inside muscular tissue, not fat gain
Most people experience side effects About 80 percent of adults taking tirzepatide or semiglutide, the active ingredients in the most commonly prescribed GLP-1s, experienced at least one side effect, according to a 2024 review study published in the journal Obesity Pillars
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study
